Detroit, MI
Peptide Therapy clinics in Detroit
Detroit has a metro Detroit market with anchor hospitals and a growing longevity scene in the suburbs, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Birmingham, Royal Oak, Grosse Pointe, and Troy range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Henry Ford Health, Beaumont, and DMC network. The scene here skews toward clinics concentrated in the wealthier Oakland County suburbs. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Detroit clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Detroit Hormone Replacement Therapy Clinic
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
Detroit Peptide
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
Regulatory context
A note on Michigan's peptide therapy rules.
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional compounding pharmacies; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
-
Michigan Public Health Code (Public Act 368 of 1978, Part 177 Pharmacy)
Governs pharmacy licensure and compounding under the Michigan Board of Pharmacy. -
Michigan Public Health Code Part 170 (Medicine)
Regulates physician prescribing and delegation. -
Michigan Administrative Code R 338.471 et seq.
Implements compounding rules consistent with USP 795 and 797.
The Michigan Board of Pharmacy under the Department of Licensing and Regulatory Affairs (LARA) inspects compounding pharmacies for USP compliance. Non-resident pharmacies shipping peptides into Michigan must hold a current non-resident license. The Board publishes disciplinary actions and coordinates with LARA inspectors.